Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB-0998 for residual neuropathy in eosinophilic granulomatosis with polyangiitis
jRCT2041220136Active, not recruiting
- Sponsor
- Japan Blood Products Organization
- Start
- Jan 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial of polyvalent human immunoglobulin in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by Japan Blood Products Organization. Primary endpoint: Change from baseline in sum MMT score at 4 weeks. Started Jan 2023; status: active, not recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on jRCT2041220136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220136.